Treatment of severe life threatening hypocalcemia with recombinant human teriparatide in patients with postoperative hypoparathyroidism - a case series.

Treatment of severe life threatening hypocalcemia with recombinant human teriparatide in patients with postoperative hypoparathyroidism - a case series. Endokrynol Pol. 2016 Jul 8; Authors: Andrysiak-Mamos E, Żochowska E, Kaźmierczyk-Puchalska A, Popow M, Kaczmarska-Turek D, Pachucki J, Bednarczuk T, Syrenicz A Abstract Hypocalcemia is a common postoperative complication, both after the resection of parathyroid adenoma associated with primary hyperparathyroidism, and after total thyroidectomy due to thyroid cancer or nodular goiter. For a few years, in patients with postoperative hypoparathyroidism and severe hypocalcemia, who cannot discontinue intravenous calcium preparations, even with the use of high vitamin D doses, attempts have been made to add recombinant human parathormone (rhPTH) to treatment schedule. In this work, for the first time in Poland we demonstrate the potential use of teriparatide for the treatment of severe hypocalcemia based on three different cases of postoperative hypoparathyroidism. CASE 1: Female (52) with postoperative hypoparathyroidism, after total thyroidectomy and the removal of lower left parathyroid gland due to hyperparathyroidism, several weeks after the surgery still required intravenous calcium infusions because of tetany symptoms. Just one month of teriparatide treatment at 20 µg/0.08 ml given in daily subcutaneous injections proved sufficient to control calcium levels with oral cal...
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research